Mycolic acid synthase (not a single enzyme but a class of enzymes involved in mycolic acid synthesis)

The term "Mycobacterial protein synthesis" is not specific enough to identify a single protein, enzyme, or receptor target. In the context of mycobacteria such as Mycobacterium tuberculosis, a major therapeutic target is the biosynthesis of the cell wall, particularly the synthesis of mycolic acids—long-chain fatty acids critical for the impermeability and virulence of the mycobacterial cell envelope. Several enzymes are involved in this pathway, but the most clinically relevant target is mycolic acid synthase (though this is a general term, not a single enzyme). The canonical first-line antitubercular drug isoniazid (INH) inhibits the synthesis of mycolic acids by targeting multi-functional fatty acid synthases involved in this process[6]. Unlike a single, specific and well-characterized target (like an enzyme or receptor), "Mycobacterial protein synthesis" is too broad and generic—it could refer to the general process of protein synthesis in mycobacteria (which is a common target of protein synthesis inhibitors like chloramphenicol or kanamycin)[6], but these are not specific to mycobacteria and are not what is usually meant by the "target" in the context of anti-tubercular therapy. Thus, this entry is not a specific, canonical, or actionable target in the way typically required for structured drug discovery.

Inhibition of mycolic acid synthesis, disruption of cell wall integrity[6]